Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_assertion type Assertion NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_head.
- NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_assertion description "[Examine therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma/that efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_provenance.
- NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_assertion evidence source_evidence_literature NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_provenance.
- NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_assertion SIO_000772 15838262 NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_provenance.
- NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_assertion wasDerivedFrom lhgdn-20090331 NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_provenance.
- NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_assertion wasGeneratedBy ECO_0000203 NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_provenance.